| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e472e52510b9a0150fb8bb983e5c5a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-712
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
| filingDate |
2020-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a796160f6d116ae0c8a95a3ba0ee5fa8 |
| publicationDate |
2020-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020111607-A |
| titleOfInvention |
Peptide oligonucleotide conjugate |
| abstract |
PROBLEM TO BE SOLVED: To provide a peptide oligonucleotide conjugate. Provided are oligonucleotide analogs conjugated to a carrier peptide. The compounds of the present disclosure are useful in the treatment of a variety of diseases, such as those that result in a beneficial therapeutic effect by inhibiting protein expression or modifying aberrant mRNA splicing products. In one embodiment of the present disclosure, (a) a carrier peptide comprising an amino acid subunit; and (b) a nucleic acid analog comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid. Two or more of the amino acid subunits are positively charged amino acids, and the carrier peptide contains a glycine (G) or proline (P) amino acid at the carboxy terminus of the carrier peptide. , The carrier peptide is covalently attached to the nucleic acid analog. [Selection diagram] Figure 1C |
| priorityDate |
2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |